Boston Scientific achieves this introduction of Endura Weight Loss Solutions, an expansion of minimally invasive and drug-adjacent portfolios to treat obesity through nationally aware awareness initiatives.

Boston Scientific has introduced a new class of minimally invasive procedures the Endura Weight Loss Solutions, in an attempt to treat obesity as well as enhance patient outcomes. Survey data indicating 74 percent of women consider weight loss a crucial part of health is corroborated with the concept of the launch, with many women not able to reach permanent results.

The program fits in the wider healthcare and medicine environment, providing an option to people who do not want to take some long-lasting weight loss drugs or undergo invasive interventions and operations. Endura provides endoscopic sleeve gastroplasty (ESG) and the Orbera Intragastric Balloon System. The procedures aimed at stomach reduction volumes without making external incisions.

Boston Scientific, the medical device and pharmaceutical-related innovator has marketed these solutions as clinically substantiated solutions with quicker healing times. ESG is reported to minimize stomach volume up to 80 percent, whereas the Orbera balloon assists patients to feel satiated faster and longer term.

One of the main findings of the survey indicated that nearly half of women (47%) did not know that endoscopic weight loss existed, and a concern of the before-and-after analysis of the video clips was the low level of awareness of the subject. In response, Boston Scientific is marketing the minimally invasive, pharmaceuticals-adjacent weight loss procedures through the “Break Through” campaign.

The activities of the company are directed to empower patients to have better and more accessible weight loss solutions that can fill that gap between lifestyle changes, medical interventions, and innovative treatment options.